問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏志傑

Recruiting

List

103Cases

2023-09-01 - 2027-04-30

Phase II

Active
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Budigalimab (ABBV-181)；Livmoniplimab (ABBV-151)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2024-01-01 - 2030-11-30

Phase II/III

Active
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment –LIVIGNO-2

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Livmoniplimab (ABBV-151)；Budigalimab (ABBV-181)

Participate Sites
5Sites

Recruiting5Sites

2024-02-01 - 2038-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-02-01 - 2030-01-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma

  • Test Drug

    Epcoritamab

Participate Sites
4Sites

Recruiting4Sites

2022-10-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Epcoritamab

Participate Sites
5Sites

Recruiting5Sites

2023-10-31 - 2027-12-31

Phase II

Active
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/​Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Neoplasms, Head and Neck

  • Test Drug

    JEMPERLIBelrestotugGSK6097608

Participate Sites
4Sites

Recruiting4Sites

2021-12-31 - 2025-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-06-16 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-06-11 - 2030-12-31

Phase III

Active
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    靜脈點滴注射劑

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB